Skip to main content
SpringerLink
Log in

Multifunctional Opioid Ligands

  • Chapter
  • First Online:
Delta Opioid Receptor Pharmacology and Therapeutic Applications

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 247))

Abstract

The opioid receptor system plays a major role in the regulation of mood, reward, and pain. The opioid receptors therefore make attractive targets for the treatment of many different conditions, including pain, depression, and addiction. However, stimulation or blockade of any one opioid receptor type often leads to on-target adverse effects that limit the clinical utility of a selective opioid agonist or antagonist. Literature precedent suggests that the opioid receptors do not act in isolation and that interactions among the opioid receptors and between the opioid receptors and other proteins may produce clinically useful targets. Multifunctional ligands have the potential to elicit desired outcomes with reduced adverse effects by allowing for the activation of specific receptor conformations and/or signaling pathways promoted as a result of receptor oligomerization or crosstalk. In this chapter, we describe several classes of multifunctional ligands that interact with at least one opioid receptor. These ligands have been designed for biochemical exploration and the treatment of a wide variety of conditions, including multiple kinds of pain, depression, anxiety, addiction, and gastrointestinal disorders. The structures, pharmacological utility, and therapeutic drawbacks of these classes of ligands are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abbott NJ, Romero IA (1996) Transporting therapeutics across the blood-brain barrier. Mol Med Today 2(3):106–113

    Article  CAS  PubMed  Google Scholar 

  • Aceto MD, Harris LS, Negus SS, Banks ML, Hughes LD, Akgun E, Portoghese PS (2012) MDAN-21: a bivalent opioid ligand containing mu-agonist and delta-antagonist pharmacophores and its effects in rhesus monkeys. Int J Med Chem 2012:1–6

    Google Scholar 

  • Akgun E, Javed MI, Lunzer MM, Smeester BA, Beitz AJ, Portoghese PS (2013) Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception. Proc Natl Acad Sci 110(28):11595–11599

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Akgun E, Javed MI, Lunzer MM, Powers MD, Sham YY, Watanabe Y, Portoghese PS (2015) Inhibition of inflammatory and neuropathic pain by targeting a mu opioid receptor/chemokine receptor5 heteromer (MOR-CCR5). J Med Chem 58(21):8647–8657

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Anand JP, Boyer BT, Mosberg HI, Jutkiewicz EM (2016) The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice. Psychopharmacology 233(13):2479–2487

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ananthan S, Saini SK, Dersch CM, Xu H, McGlinchey N, Giuvelis D, Bilsky EJ, Rothman RB (2012) 14-Alkoxy-and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effects. J Med Chem 55(19):8350–8363

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Arnatt CK, Falls BA, Yuan Y, Raborg TJ, Masvekar RR, El-Hage N, Selley DE, Nicola AV, Knapp PE, Hauser KF et al (2016) Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization. Bioorg Med Chem 24(22):5969–5987

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bailey CP, Connor M (2005) Opioids: cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol 5:60–68

    Article  CAS  PubMed  Google Scholar 

  • Balboni G, Guerrini R, Salvadori S, Bianchi C, Rizzi D, Bryant SD, Lazarus LH (2002) Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. J Med Chem 45(3):713–720

    Article  CAS  PubMed  Google Scholar 

  • Balboni G, Onnis V, Congiu C, Zotti M, Sasaki Y, Ambo A, Bryant SD, Jinsmaa Y, Lazarus LH, Lazzari I et al (2007) Further studies on the effect of lysine at the C-terminus of the Dmt-Tic opioid pharmacophore. Bioorg Med Chem 15(9):3143–3151

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bender AM, Griggs NW, Anand JP, Traynor JR, Jutkiewicz EM, Mosberg HI (2015) Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy mu opioid receptor/delta opioid receptor ligands. ACS Chem Neurosci 6(8):1428–1435

    Article  CAS  PubMed  Google Scholar 

  • Besson JM (1999) The neurobiology of pain. Lancet 353:1610–1615

    Article  CAS  PubMed  Google Scholar 

  • Betti C, Starnowska J, Mika J, Dyniewicz J, Frankiewicz L, Novoa A, Bochynska M, Keresztes A, Kosson P, Makuch W et al (2015) Dual alleviation of acute and neuropathic pain by fused opioid agonist-neurokinin 1 antagonist peptidomimetics. ACS Med Chem Lett 6(12):1209–1214

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bhushan RG, Sharma SK, Xie Z, Daniels DJ, Portoghese PS (2004) A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta1 and kappa2 phenotypes. Selective targeting of delta-kappa heterodimers. J Med Chem 47(12):2969–2972

    Article  CAS  PubMed  Google Scholar 

  • Bird MF, Camilla Cerlesi M, Brown M, Malfacini D, Vezzi V, Molinari P, Micheli L, Di Cesare Mannelli L, Ghelardini C, Guerrini R et al (2016) Characterisation of the novel mixed mu-NOP peptide ligand dermorphin-N/OFQ (DeNo). PLoS One 11(6):1–22

    Google Scholar 

  • Bowen CA, Stevens Negus S, Zong R, Neumeyer JL, Bidlack JM, Mello NK (2003) Effects of mixed-action kappa/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology 28:1125–1139

    Article  CAS  PubMed  Google Scholar 

  • Bushlin I, Rozenfeld R, Devi LA (2010) Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol 10(1):80–86

    Article  CAS  PubMed  Google Scholar 

  • Butour JL, Moisand C, Mazarguil H, Mollereau C, Meunier JC (1997) Recognition and activation of the opioid receptor-like ORL1 receptor by nociceptin, nociceptin analogs and opioids. Eur J Pharmacol 321(1):97–103

    Article  CAS  PubMed  Google Scholar 

  • Cahill CM, Holdridge SV, Morinville A (2007) Trafficking of delta-opioid receptors and other g-protein-coupled receptors: implications for pain and analgesia. Trends Pharmacol Sci 28(1):23–31

    Article  CAS  PubMed  Google Scholar 

  • Cami-Kobeci G, Polgar WE, Khroyan TV, Toll L, Husbands SM (2011) Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine. J Med Chem 54(19):6531–6537

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chefer VI, Shippenberg TS (2009) Augmentation of morphine-induced sensitization but reduction in morphine tolerance and reward in delta-opioid receptor knockout mice. Neuropsychopharmacology 34(4):887–898

    Article  CAS  PubMed  Google Scholar 

  • Chen C, Li J, Bot G, Szabo I, Rogers TJ, Liu-Chen LY (2004) Heterodimerization and cross-desensitization between the mu-opioid receptor and the chemokine CCR5 receptor. Eur J Pharmacol 483:175–186

    Article  CAS  PubMed  Google Scholar 

  • Chu Sin Chung P, Kieffer BL (2013) Delta opioid receptors in brain function and diseases. Pharmacol Ther 140(1):112–120

    Article  CAS  PubMed  Google Scholar 

  • Cinar R, Szucs M (2009) CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-Ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells. J Pharmacol Exp Ther 330(2):567–574

    Article  CAS  PubMed  Google Scholar 

  • Cruz A, Domingos S, Gallardo E, Martinho A (2017) A unique natural selective kappa-opioid receptor agonist, Salvinorin A, and its roles in human therapeutics. Phytochemistry 137:9–14

    Article  CAS  PubMed  Google Scholar 

  • Cueva JP, Roche C, Ostovar M, Kumar V, Clark MJ, Hillhouse TM, Lewis JW, Traynor JR, Husbands SM (2015) C7β-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors. J Med Chem 58(10):4242–4249

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cvejic S, Devi LA (1997) Dimerization of the delta opioid receptor. J Biol Chem 272(43):26959–26964

    Article  CAS  PubMed  Google Scholar 

  • Daniels DJ, Lenard NR, Etienne CL, Law PY, Roerig SC, Portoghese PS (2005a) Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci 102(52):19208–19213

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Daniels DJ, Kulkarni A, Xie Z, Bhushan RG, Portoghese PS (2005b) A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes. J Med Chem 48(6):1713–1716

    Article  CAS  PubMed  Google Scholar 

  • Deb I, Paira P, Hazra A, Banerjee S, Dutta PK, Mondal NB, Das S (2009) Synthesis and characterizations of novel quinoline derivatives having mixed ligand activities at the kappa and mu receptors: potential therapeutic efficacy against morphine dependence. Bioorg Med Chem 17(16):5782–5790

    Article  CAS  PubMed  Google Scholar 

  • Decker M, Fulton BS, Zhang B, Knapp BI, Bidlack JM, Neumeyer JL (2009) Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands. J Med Chem 52(23):7389–7396

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci 85:5274–5278

    Article  PubMed  PubMed Central  Google Scholar 

  • Dietis N (2012) Strategies to reduce morphine tolerance in cancer: evaluation of the bifunctional opioid UFP-505. University of Leicester

    Google Scholar 

  • Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG (2009) Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth 103(1):38–49

    Article  CAS  PubMed  Google Scholar 

  • Dietis N, McDonald J, Molinari S, Calo G, Guerrini R, Rowbotham DJ, Lambert DG (2012) Pharmacological characterization of the bifunctional opioid ligand H-Dmt-Tic-Gly-NH-Bzl (UFP-505). Br J Anaesth 108(2):262–270

    Article  CAS  PubMed  Google Scholar 

  • Ding H, Czoty PW, Kiguchi N, Cami-Kobeci G, Sukhtankar DD, Nader MA, Husbands SM, Ko M-C (2016) A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates. Proc Natl Acad Sci 113:E5511–E5518

    CAS  PubMed  PubMed Central  Google Scholar 

  • Do Carmo GP, Polt R, Bilsky EJ, Rice KC, Negus SS (2008) Behavioral pharmacology of the mu/delta opioid glycopeptide MMP2200 in rhesus monkeys. J Pharmacol Exp Ther 326(3):939–948

    Article  PubMed  CAS  Google Scholar 

  • Dunham JH, Hall RA (2009) Enhancement of the surface expression of G protein-coupled receptors. Trends Biotechnol 27(9):541–545

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dyniewicz J, Lipinski PF, Kosson P, Lesniak A, Bochynska-Czyz M, Muchowska A, Tourwe D, Ballet S, Misicka A, Lipkowski AW (2017) Hydrazone linker as a useful tool for preparing chimeric peptide/nonpeptide bifunctional compounds. ACS Med Chem Lett 8(1):73–77

    Article  CAS  PubMed  Google Scholar 

  • Evans RM, You H, Hameed S, Altier C, Mezghrani A, Bourinet E, Zamponi GW (2010) Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium channel regulation. J Biol Chem 285(2):1032–1040

    Article  CAS  PubMed  Google Scholar 

  • Fernández-Fernández C, Callado LF, Girón R, Sánchez E, Erdozain AM, López-Moreno JA, Morales P, de Fonseca FR, Fernández-Ruiz J, Goya P et al (2014) Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results. Drug Des Devel Ther 8:263–277

    PubMed  PubMed Central  Google Scholar 

  • George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, O’Dowd BF (2000) Oligomerization of mu- and delta-opioid receptors: generation of novel functional properties. J Biol Chem 275(34):26128–26135

    Article  CAS  PubMed  Google Scholar 

  • Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, Devi LA (2000) Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J Neurosci 20:1–5

    Article  Google Scholar 

  • Gomes I, IJzerman AP, Ye K, Maillet EL, Devi LA (2011) G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol 79(6):1044–1052

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Greedy BM, Bradbury F, Thomas MP, Grivas K, Cami-Kobeci G, Archambeau A, Bosse K, Clark MJ, Aceto M, Lewis JW et al (2013) Orvinols with mixed kappa/mu opioid receptor agonist activity. J Med Chem 56(8):3207–3216

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Grenald SA, Young MA, Wang Y, Ossipov MH, Ibrahim MM, Largent-Milnes TM, Vanderah TW (2017) Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists. Neuropharmacology 116:59–70

    Article  CAS  PubMed  Google Scholar 

  • Guillemyn K, Starnowska J, Lagard C, Dyniewicz J, Rojewska E, Mika J, Chung NN, Utard V, Kosson P, Lipkowski AW et al (2016) Bifunctional peptide-based opioid agonist-nociceptin antagonist ligands for dual treatment of acute and neuropathic pain. J Med Chem 59(8):3777–3792

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Günther T, Dasgupta P, Mann A, Miess E, Kliewer A, Fritzwanker S, Steinborn R, Schulz S (2017) Targeting multiple opioid receptors – improved analgesics with reduced side effects? Br J Pharmacol.

    Google Scholar 

  • Harland AA, Yeomans L, Griggs NW, Anand JP, Pogozheva ID, Jutkiewicz EM, Traynor JR, Mosberg HI (2015) Further optimization and evaluation of bioavailable, mixed-efficacy mu-opioid receptor (MOR) agonists/delta-opioid receptor (DOR) antagonists: balancing MOR and DOR affinities. J Med Chem 58(22):8952–8969

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Healy JR, Bezawada P, Shim J, Jones JW, Kane MA, MacKerell AD, Coop A, Matsumoto RR (2013) Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities. ACS Chem Neurosci 4(9):1256–1266

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Heyman JS, Vaught JL, Mosberg HI, Haaseth RC, Porreca F (1989a) Modulation of mu-mediated antinociception by delta agonists in the mouse: selective potentiation of morphine and normorphine by [D-Pen2, D-Pen5]enkephalin. Eur J Pharmacol 165(1):1–10

    Article  CAS  PubMed  Google Scholar 

  • Heyman JS, Jiang Q, Rothman RB, Mosberg HI, Porreca F (1989b) Modulation of mu-mediated antinociception by delta agonists: characterization with antagonists. Eur J Pharmacol 169:43–52

    Article  CAS  PubMed  Google Scholar 

  • Hiebel AC, Yong SL, Bilsky E, Giuvelis D, Deschamps JR, Parrish DA, Aceto MD, May EL, Harris LS, Coop A et al (2007) Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure – activity relationships of a potent μ-agonist δ-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-Hydroxyphenyl)-N-phenylethylmorphan series. J Med Chem 50(16):3765–3776

    Article  CAS  PubMed  Google Scholar 

  • Horan P, Tallarida RJ, Haaseth RC, Matsunaga TO, Hruby VJ, Porreca F (1992) Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: supra- and sub-additivity. Life Sci 50:1535–1541

    Article  CAS  PubMed  Google Scholar 

  • Horan PJ, Mattia A, Bilsky EJ, Weber S, Davis TP, Yamamura HI, Malatynska E, Appleyard SM, Slaninova J, Misicka A (1993) Antinociceptive profile of biphalin, a dimeric enkephalin analog. J Pharmacol Exp Ther 265:1446–1454

    CAS  PubMed  Google Scholar 

  • Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, International Union of Pharmacology et al (2002) XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54(2):161–202

    Article  CAS  PubMed  Google Scholar 

  • Huang P, Tunis J, Parry C, Tallarida R, Liu-Chen LY (2016) Synergistic antidepressant-like effects between a kappa opioid antagonist (LY2444296) and a delta opioid agonist (ADL5859) in the mouse forced swim test. Eur J Pharmacol 781:53–59

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE (2009) Monitoring the future: national survey results on drug use, 1975–2008, vol 1. NIH Publication No. 09–7402, pp 1–721

    Google Scholar 

  • Journigan VB, Polgar WE, Khroyan TV, Zaveri NT (2014) Designing bifunctional nop receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II. Bioorg Med Chem 22(8):2508–2516

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Jutkiewicz EM (2006) The antidepressant-like effects of delta-opioid receptor agonists. Mol Interv 6(3):162–169

    Article  CAS  PubMed  Google Scholar 

  • Kawano S, Ambo A, Sasaki Y (2006) Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-amide. Bioorg Med Chem Lett 16(18):4839–4841

    Article  CAS  PubMed  Google Scholar 

  • Kawano S, Ito R, Nishiyama M, Kubo M, Matsushima T, Minamisawa M, Ambo A, Sasaki Y (2007) Receptor binding properties and antinociceptive effects of chimeric peptides consisting of a mu-opioid receptor agonist and an ORL1 receptor antagonist. Biol Pharm Bull 30(7):1260–1264

    Article  CAS  PubMed  Google Scholar 

  • Kest B, Lee CE, McLemore GL, Inturrisi CE (1996) An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice. Brain Res Bull 39(3):185–188

    Article  CAS  PubMed  Google Scholar 

  • Khroyan TV, Zaveri NT, Polgar WE, Orduna J, Olsen C, Jiang F, Toll L (2007) SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-Yl)piperidin-4-Yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice. J Pharmacol Exp Ther 320(2):934–943

    Article  CAS  PubMed  Google Scholar 

  • Khroyan TV, Polgar WE, Cami-kobeci G, Husbands SM, Zaveri NT, Toll L (2011a) The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-Yl]-3,3-dimethylpentan-2-Ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse mode. J Pharmacol Exp Ther 336(3):952–961

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Khroyan TV, Polgar WE, Orduna J, Montenegro J, Jiang F, Zaveri NT, Toll L (2011b) Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/mu receptor agonists in the sciatic nerve ligation chronic pain model in mice. J Pharmacol Exp Ther 339(2):687–693

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kiguchi N, Ding H, Ko MC (2016) Central N/OFQ-NOP receptor system in pain modulation. In: Advances in pharmacology, vol 75. Elsevier, Amsterdam, pp 217–243

    Google Scholar 

  • Kleczkowska P, Lipkowski AW, Tourwé D, Ballet S (2013) Hybrid opioid/non-opioid ligands in pain research. Curr Pharm Des 19:7435–7450

    Article  CAS  PubMed  Google Scholar 

  • Kumar V, Clark MJ, Traynor JR, Lewis JW, Husbands SM (2014a) Pyrrolo- and pyridomorphinans: non-selective opioid antagonists and delta opioid agonists/mu opioid partial agonists. Bioorg Med Chem 22(15):4067–4072

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kumar V, Ridzwan IE, Grivas K, Lewis JW, Clark MJ, Meurice C, Jimenez-Gomez C, Pogozheva I, Mosberg H, Traynor JR et al (2014b) Selectively promiscuous opioid ligands: discovery of high affinity/low efficacy opioid ligands with substantial nociceptin opioid peptide receptor affinity. J Med Chem 57(10):4049–4057

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lagard C, Chevillard L, Guillemyn K, Risede P, Laplanche J-L, Spetea M, Ballet S, Megarbane B (2017) Bifunctional peptide-based opioid agonist/nociceptin antagonist ligand for dual treatment of nociceptive and neuropathic pain. Pain 158(3):505–515

    Article  CAS  PubMed  Google Scholar 

  • Lambert DG, Bird MF, Rowbotham DJ (2015) Cebranopadol: a first in-class example of a nociceptin/orphanin FQ receptor and opioid receptor agonist. Br J Anaesth 114(3):364–366

    Article  CAS  PubMed  Google Scholar 

  • Lapalu S, Moisand C, Mazarguil H, Cambois G, Mollereau C, Meunier JC (1997) Comparison of the structure-activity relationships of nociceptin and dynorphin a using chimeric peptides. FEBS Lett 417(3):333–336

    Article  CAS  PubMed  Google Scholar 

  • Law PY, Erickson-Herbrandson LJ, Zha QQ, Solberg J, Chu J, Sarre A, Loh HH (2005) Heterodimerization of mu- and delta-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions. J Biol Chem 280(12):11152–11164

    Article  CAS  PubMed  Google Scholar 

  • Le Naour M, Akgun E, Yekkirala A, Lunzer MM, Powers MD, Kalyuzhny AE, Portoghese PS (2013) Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance. J Med Chem 56:5505–5513

    Article  PubMed  CAS  Google Scholar 

  • Lenard NR, Daniels DJ, Portoghese PS, Roerig SC (2007) Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores. Eur J Pharmacol 566:75–82

    Article  CAS  PubMed  Google Scholar 

  • Li T, Shiotani K, Miyazaki A, Tsuda Y, Ambo A, Sasaki Y, Jinsmaa Y, Marczak E, Bryant SD, Lazarus LH et al (2007) Bifunctional [2′,6′-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands. J Med Chem 50(12):2753–2766

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li Y, Lefever MR, Muthu D, Bidlack JM, Bilsky EJ, Polt R (2012) Opioid glycopeptide analgesics derived from endogenous enkephalins and endorphins. Future Med Chem 4(2):205–226

    Article  CAS  PubMed  Google Scholar 

  • Linz K, Christoph T, Tzschentke TM, Koch T, Schiene K, Gautrois M, Schröder W, Kögel BY, Beier H, Englberger W et al (2014) Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist. J Pharmacol Exp Ther 349(3):535–548

    Article  PubMed  CAS  Google Scholar 

  • Liu NJ, Xu T, Xu C, Li CQ, Yu YX, Kang HG, Han JS (1995) Cholecystokinin octapeptide reverses mu-opioid-receptor-mediated inhibition of calcium current in rat dorsal root ganglion neurons. J Pharmacol Exp Ther 275(3):1293–1299

    CAS  PubMed  Google Scholar 

  • Lowery JJ, Raymond TJ, Giuvelis D, Bidlack JM, Polt R, Bilsky EJ (2011) In vivo characterization of MMP-2200, a mixed delta/mu opioid agonist, in mice. J Pharmacol Exp Ther 336(3):767–778

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lufty K, Cowan A (2004) Buprenorphine : a unique drug with complex pharmacology. Curr Neuropharmacol 2(4):395–402

    Article  Google Scholar 

  • Lutz PE, Kieffer BL (2013) Opioid receptors: distinct roles in mood disorders. Trends Neurosci 36(3):195–206

    Article  CAS  PubMed  Google Scholar 

  • Mabrouk OS, Marti M, Salvadori S, Morari M (2009) The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway. Neuroscience 164(2):360–369

    Article  CAS  PubMed  Google Scholar 

  • Mabrouk OS, Viaro R, Volta M, Ledonne A, Mercuri N, Morari M (2014) Stimulation of delta opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism. J Neurosci 34(39):12953–12962

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Maisonneuve IM, Archer S, Glick SD (1994) U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett 181:57–60

    Article  CAS  PubMed  Google Scholar 

  • Martin TJ, Kim SA, Cannon DG, Sizemore GM, Bian D, Porreca F, Smith JE (2000) Antagonism of delta(2) opioid receptors by Naltrindole-5′-isothiocyanate attenuates heroin self-administration but not antinociception in rats. J Pharmacol Exp Ther 294(3):975–982

    CAS  PubMed  Google Scholar 

  • Mello NK, Negus SS (1998) Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J Pharmacol Exp Ther 286(2):812–824

    CAS  PubMed  Google Scholar 

  • Mello NK, Mendelson JH, Sholar MB, Jaszyna-Gasior M, Goletiani N, Siegel AJ (2005) Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men. Neuropsychopharmacology 30(3):618–632

    Article  CAS  PubMed  Google Scholar 

  • Mizoguchi H, Hung KC, Leitermann R, Narita M, Nagase H, Suzuki T, Tseng LF (2003) Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice. Eur J Pharmacol 461(1):35–39

    Article  CAS  PubMed  Google Scholar 

  • Mollica A, Pelliccia S, Famiglini V, Stefanucci A, Macedonio G, Chiavaroli A, Orlando G, Brunetti L, Ferrante C, Pieretti S et al (2017) Exploring the first rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors. J Enzyme Inhib Med Chem 32(1):444–451

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Morphy R, Rankovic Z (2009) Designing multiple ligands – medicinal chemistry strategies and challenges. Curr Pharm Des 15(6):587–600

    Article  CAS  PubMed  Google Scholar 

  • Morphy R, Kay C, Rankovic Z (2004) From magic bullets to designed multiple ligands. Res Focus Rev 9(15):641–652

    CAS  Google Scholar 

  • Mosberg HI, Yeomans L, Harland AA, Bender AM, Sobczyk-kojiro K, Anand JP, Clark MJ, Jutkiewicz EM, Traynor JR (2013) Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy mu opioid receptor (MOR) agonist/delta opioid receptor (DOR) antagonist ligands. J Med Chem 56:2139–2149

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mosberg HI, Yeomans L, Anand JP, Porter V, Sobczyk-Kojiro K, Traynor JR, Jutkiewicz EM (2014) Development of a bioavailable μ opioid receptor (MOPr) agonist, δ opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance. J Med Chem 57(7):3148–3153

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mustazza C, Bastanzio G (2011) Development of nociceptin receptor (NOP) agonists and antagonists. Med Res Rev 31(4):605–648

    Article  CAS  PubMed  Google Scholar 

  • Nair P, Yamamoto T, Largent-Milnes TM, Cowell S, Kulkarni V, Moye S, Navratilova E, Davis P, Ma SW, Vanderah TW et al (2013) Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities. Bioorg Med Chem Lett 23(17):4975–4978

    Article  CAS  PubMed  Google Scholar 

  • Nair P, Yamamoto T, Cowell S, Kulkarni V, Moye S, Navratilova E, Davis P, Ma SW, Vanderah TW, Lai J et al (2015) Discovery of tripeptide-derived multifunctional ligands possessing delta/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities. Bioorg Med Chem Lett 25(17):3716–3720

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Negus SS, Mello NK, Portoghese PS, Lin CE (1997) Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther 282(1):44–55

    CAS  PubMed  Google Scholar 

  • Neumeyer JL, Bidlack JM, Zong R, Bakthavachalam V, Gao P, Cohen DJ, Negus SS, Mello NK (2000) Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence. J Med Chem 43(1):114–122

    Article  CAS  PubMed  Google Scholar 

  • Neumeyer JL, Zhang A, Xiong W, Gu X-H, Hilbert JE, Knapp BI, Negus SS, Mello NK, Bidlack JM (2003) Design and synthesis of novel dimeric morphinan ligands for kappa and mu opioid receptors. J Med Chem 46(24):5162–5170

    Article  CAS  PubMed  Google Scholar 

  • Neumeyer JL, Zhang B, Zhang T, Sromek AW, Knapp BI, Cohen DJ, Bidlack JM (2013) Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors. J Med Chem 55(8):3878–3890

    Article  CAS  Google Scholar 

  • Nielsen S, Sabioni P, Trigo JM, Ware MA, Betz-Stablein BD, Murnion B, Lintzeris N, Khor KE, Farrell M, Smith A et al (2017) Opioid-sparing effect of cannabinoids: a systematic review and meta-analysis. Neuropsychopharmacology 42:1752–1765

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Noda Y, Mamiya T, Nabeshima T, Nishi M, Higashioka M, Takeshima H (1998) Loss of antinociception induced by naloxone benzoylhydrazone in nociceptin receptor-knockout mice. J Biol Chem 273(29):18047–18051

    Article  CAS  PubMed  Google Scholar 

  • Peng X, Knapp BI, Bidlack JM, Neumeyer JL (2006) Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors. J Med Chem 49(1):256–262

    Article  CAS  PubMed  Google Scholar 

  • Peng J, Sarkar S, Chang SL (2012) Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR. Drug Alcohol Depend 124:223–228

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Perlikowska R, Piekielna J, Gentilucci L, De Marco R, Cerlesi MC, Calo G, Artali R, Tömböly C, Kluczyk A, Janecka A (2016) Synthesis of mixed MOR/KOR efficacy cyclic opioid peptide analogs with antinociceptive activity after systemic administration. Eur J Med Chem 109:276–286

    Article  CAS  PubMed  Google Scholar 

  • Pinto M, Sousa M, Lima D, Tavares I (2008) Participation of mu-opioid, GABA(B), and NK1 receptors of major pain control medullary areas in pathways targeting the rat spinal cord: implications for descending modulation of nociceptive transmission. J Comp Neurol 510(2):175–187

    Article  CAS  PubMed  Google Scholar 

  • Polt R, Dhanasekaran M, Keyari CM (2005) Glycosylated neuropeptides: a new vista for neuropsychopharmacology? Med Res Rev 25(5):557–585

    Article  CAS  PubMed  Google Scholar 

  • Portoghese PS, Akgun E, Lunzer MM (2017) Heteromer induction: an approach to unique pharmacology? ACS Chem Neurosci 8(3):426–428

    Article  CAS  PubMed  Google Scholar 

  • Pradhan AA, Befort K, Nozaki C, Gavériaux-Ruff C, Kieffer BL (2011) The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci 32(10):581–590

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Provencher BA, Sromek AW, Li W, Russell S, Chartoff E, Knapp BI, Bidlack JM, Neumeyer JL (2013) Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors. J Med Chem 56(21):8872–8878

    Article  CAS  PubMed  Google Scholar 

  • Qi JN, Mosberg HI, Porreca F (1990) Modulation of the potency and efficacy of mu-mediated antinociception by delta agonist in the mouse. J Pharmacol Exp Ther 254(2):683–689

    CAS  PubMed  Google Scholar 

  • Reinscheid RK, Higelin J, Henningsen RA, Monsma FJ, Civelli O (1998) Structures that delineate orphanin FQ and dynorphin a pharmacological selectivities. J Biol Chem 273(3):1490–1495

    Article  CAS  PubMed  Google Scholar 

  • Rios CD, Jordan BA, Gomes I, Devi LA (2001) G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol Ther 92:71–87

    Article  CAS  PubMed  Google Scholar 

  • Rios C, Gomes I, Devi LA (2009) μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148(4):387–395

    Article  CAS  Google Scholar 

  • Ross S, Peselow E (2009) The neurobiology of addictive disorders. Clin Neuropharmacol 32(5):269–276

    Article  CAS  PubMed  Google Scholar 

  • Rowland NE, Mukherjee M, Robertson K (2002) Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology 159(1):111–116

    Article  CAS  Google Scholar 

  • Rozenfeld R, Abul-Husn NS, Gomez I, Devi LA (2007) An emerging role for the delta opioid receptor in the regulation of mu opioid receptor function. Sci World J 7(S2):64–73

    Article  Google Scholar 

  • Salvadori S, Guerrini R, Balboni G, Bianchi C, Bryant SD, Cooper PS, Lazarus LH (1999) Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism. J Med Chem 42(24):5010–5019

    Article  CAS  PubMed  Google Scholar 

  • Schiller PW (2010) Bi- or multifunctional opioid peptide drugs. Life Sci 86:598–603

    Article  CAS  PubMed  Google Scholar 

  • Schiller PW, Fundytus ME, Merovitz L, Weltrowska G, Nguten TM-D, Lemieux C, Chung NN, Coderre TJ (1999) The opioid mu agonist/delta antagonist DIPP-NH2(psi) produces a potent analgesic effect, no physical dependence and less tolerance than morphine in rats. J Med Chem 42(18):3520–3526

    Article  CAS  PubMed  Google Scholar 

  • Schröder H, Wu DF, Seifert A, Rankovic M, Schulz S, Höllt V, Koch T (2009) Allosteric modulation of metabotropic glutamate receptor 5 affects phosphorylation, internalization, and desensitization of the mu-opioid receptor. Neuropharmacology 56(4):768–778

    Article  PubMed  CAS  Google Scholar 

  • Seki T, Awamura S, Kimura C, Ide S, Sakano K, Minami M, Nagase H, Satoh M (1999) Pharmacological properties of TRK-820 on cloned mu-, delta- and kappa-opioid receptors and nociceptin receptor. Eur J Pharmacol 376:159–167

    Article  CAS  PubMed  Google Scholar 

  • Smeester BA, Lunzer MM, Akgun E, Beitz AJ, Portoghese PS (2014) Targeting putative mu opioid/metabotropic glutamate receptor-5 heteromers produces potent antinociception in a chronic murine bone cancer model. Eur J Pharmacol 743:48–52

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Spagnolo B, Calo G, Polgar WE, Jiang F, Olsen CM, Berzetei-Gurske I, Khroyan TV, Husbands SM, Lewis JW, Toll L et al (2008) Activities of mixed NOP and mu-opioid receptor ligands. Br J Pharmacol 153(3):609–619

    Article  CAS  PubMed  Google Scholar 

  • Sukhtankar DD, Zaveri NT, Husbands SM, Ko M-C (2013) Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/mu-opioid receptor ligands in mouse models of neuropathic and inflammatory pain. J Pharmacol Exp Ther 346:11–22

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Suzuki S, Chuang LF, Yau P, Doi RH, Chuang RY (2002) Interactions of opioid and chemokine receptors: oligomerization of mu, kappa, and delta with CCR5 on immune cells. Exp Cell Res 280(2):192–200

    Article  CAS  PubMed  Google Scholar 

  • Tallett AJ, Blundell JE, Rodgers RJ (2009) Effects of acute low-dose combined treatment with naloxone and AM 251 on food intake, feeding behaviour and weight gain in rats. Pharmacol Biochem Behav 91(3):358–366

    Article  CAS  PubMed  Google Scholar 

  • Taylor AMW, Roberts KW, Pradhan AA, Akbari HA, Walwyn W, Lutfy K, Carroll FI, Cahill CM, Evans CJ (2015) Anti-nociception mediated by a κ opioid receptor agonist is blocked by a δ receptor agonist. Br J Pharmacol 172(2):691–703

    Article  CAS  PubMed  Google Scholar 

  • Toll L, Khroyan TV, Polgar WE, Jiang F, Olsen C, Zaveri NT (2009) Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications. J Pharmacol Exp Ther 331(3):954–964

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Toll L, Khroyan TV, Polgar WE, Husbands SM, Zaveri NT, Lucie PS, International, S. R. I, Ave R, Park M, Ba B et al (2013) Pharmacology of mixed NOP/mu ligands. In: Research and development of opioid-related ligands. American Chemical Society, Washington, pp 369–391

    Chapter  Google Scholar 

  • Toll L, Bruchas MR, Calo’ G, Cox BM, Zaveri NT (2016) Nociceptin/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems. Pharmacol Rev 68(2):419–457

    Article  PubMed  PubMed Central  Google Scholar 

  • Vang D, Paul JA, Nguyen J, Tran H, Vincent L, Yasuda D, Zaveri NT, Gupta K (2015) Small-molecule nociceptin receptor agonist ameliorates mast cell activation and pain in sickle mice. Haematologica 100(12):1517–1525

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Waldhoer M, Fong J, Jones RM, Lunzer MM, Sharma SK, Kostenis E, Portoghese PS, Whistler JL (2005) A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci 102(25):9050–9055

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang Y, Tao Y, Li F, Wang Y, Xu X, Chen J, Cao Y, Chi Z, Neumeyer JL, Zhang A et al (2009) Pharmacological characterization of ATPM [(−)-3-amino-thiazolo[5,4-B]-N-cyclopropylmethylmorphianan hydrochloride], a novel mixed kappa-agonist and mu-agonist/−antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior. J Pharmacol Exp Ther 329(1):306–313

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang H-B, Zhao B, Zhong Y-Q, Li K-C, Li Z-Y, Wang Q, Lu Y-J, Zhang Z-N, He S-Q, Zheng H-C et al (2010) Coexpression of δ- and μ-opioid receptors in nociceptive sensory neurons. Proc Natl Acad Sci 107(29):13117–13122

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wen Q, Yu G, Li YL, Yan LD, Gong ZH (2011) Pharmacological mechanisms underlying the antinociceptive and tolerance effects of the 6,14-bridged oripavine compound 030418. Acta Pharmacol Sin 32(10):1215–1224

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Williams DA, Zheng Y, David BG, Yuan Y, Zaidi SA, Stevens DL, Scoggins KL, Selley DE, Dewey WL, Akbarali HI et al (2016) 6β-N-heterocyclic substituted naltrexamine derivative BNAP: a peripherally selective mixed MOR/KOR ligand. ACS Chem Neurosci 7(8):1120–1129

    Article  CAS  PubMed  Google Scholar 

  • Wright FL, Rodgers RJ (2013) Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats. Psychopharmacology 226:415–431

    Article  CAS  PubMed  Google Scholar 

  • Xiao J, Zeng S, Wang X, Babazada H, Li Z, Liu R, Yu W (2016) Neurokinin 1 and opioid receptors: relationships and interactions in nervous system. Transl Perioper Pain Med 19(3):11–21

    Google Scholar 

  • Xie Z, Xie Z, Bhushan RG, Bhushan RG, Daniels DJ, Daniels DJ, Portoghese PS, Portoghese PS (2005) Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells. Mol Pharmacol 68(4):1079–1086

    Article  CAS  PubMed  Google Scholar 

  • Yamamoto T, Nair P, Davis P, Ma S, Navratilova E, Moye S, Tumati S, Lai J, Vanderah TW, Yamamura HI et al (2007) Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists. J Med Chem 50(12):2779–2786

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yu G, Di Yan L, Li YL, Wen Q, Dong HJ, Gong ZH (2011) TH-030418: a potent long-acting opioid analgesic with low dependence liability. Naunyn Schmiedeberg’s Arch Pharmacol 384(2):125–131

    Article  CAS  Google Scholar 

  • Yuan Y, Arnatt CK, Li G, Haney KM, Ding D, Jacob JC, Selley DE, Zhang Y (2012) Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5. Org Biomol Chem 10(13):2633

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yuan Y, Arnatt CK, El-Hage N, Dever SM, Jacob JC, Selley DE, Hauser KF, Zhang Y (2013) A bivalent ligand targeting the putative mu opioid receptor and chemokine receptor CCR5 heterodimers: binding affinity versus functional activities. Med Chem Commun 4(5):847–851

    Article  CAS  Google Scholar 

  • Zádor F, Kocsis D, Borsodi A, Benyhe S (2014) Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity. Neurochem Int 67(1):14–22

    Article  PubMed  CAS  Google Scholar 

  • Zaveri NT, Jiang F, Olsen C, Polgar WE, Toll L (2013) Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I. Bioorg Med Chem Lett 23(11):3308–3313

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang A, Xiong W, Hilbert JE, DeVita EK, Bidlack JM, Neumeyer JL (2004) 2-aminothiazole-derived opioids. Bioisosteric replacement of phenols. J Med Chem 47(8):1886–1888

    Article  CAS  PubMed  Google Scholar 

  • Zhang S, Yekkirala A, Tang Y, Portoghese PS (2009) A bivalent ligand (KMN-21) antagonist for mu/kappa heterodimeric opioid receptors. Bioorg Med Chem Lett 19(24):6978–6980

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang T, Yan Z, Sromek A, Knapp BI, Scrimale T, Bidlack JM, Neumeyer JL (2011a) Aminothiazolomorphinans with mixed κ and μ opioid activity. J Med Chem 54(6):1903–1913

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang B, Zhang T, Sromek AW, Scrimale T, Bidlack JM, Neumeyer JL (2011b) Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for kappa, mu, and delta opioid receptors. Bioorg Med Chem 19(9):2808–2816

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhu Y, King MA, Schuller AGP, Nitsche JF, Reidl M, Elde RP, Unterwald E, Pasternak GW, Pintar JE (1999) Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 24:243–252

    Article  CAS  PubMed  Google Scholar 

  • ZieliÅ„ska M, Jarmuz A, SaÅ‚aga M, Lipkowski AW, Fichna J (2016) Mixed MOP/DOP agonist biphalin elicits anti-transit effect in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms. Pharmacol Rep 68(1):32–36

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, Medical School and the Edward F. Domino Research Center, University of Michigan, Ann Arbor, MI, USA

    Jessica P. Anand

  2. Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA

    Deanna Montgomery

Authors
  1. Jessica P. Anand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deanna Montgomery
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jessica P. Anand .

Editor information

Editors and Affiliations

  1. Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, USA

    Emily M. Jutkiewicz

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Anand, J.P., Montgomery, D. (2018). Multifunctional Opioid Ligands. In: Jutkiewicz, E. (eds) Delta Opioid Receptor Pharmacology and Therapeutic Applications. Handbook of Experimental Pharmacology, vol 247. Springer, Cham. https://doi.org/10.1007/164_2018_104

Download citation

Publish with us

Policies and ethics

Search

Navigation